Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Wimbledon Championships
Heatwaves
Stock Markets
Artificial Intelligence
Social Media
Donald Trump
Taxes
NHL
Republican Party
United Nations
Soccer
US Politics
Published • loading... • Updated

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Summary by Ground News
The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration. About 80 people in the United States are diagnosed with ASPS every year. About a third of patients responded to the treatment with some degree of tumor shrinkage.

5 Articles

All
Left
Center
2
Right
News MedicalNews Medical
Center

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

·United States
Read Full Article
Medical XpressMedical Xpress
Center

Clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug ...

Read Full Article
National Cancer InstituteNational Cancer Institute

Atezolizumab approved for advanced alveolar soft part sarcoma

A clinical trial led by NCI has resulted in FDA approval of the immunotherapy drug atezolizumab (Tecentriq) to treat advanced alveolar soft part sarcoma.

Read Full Article
dcbn.orgdcbn.org

NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma – Washington DC Maryland Virginia Biotech Networks

Read Full Article
National Institutes of Health (NIH)…National Institutes of Health (NIH)…

NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma

ASPS is an extremely rare cancer that affects mostly adolescents and young adults.

·Washington, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Wednesday, December 28, 2022.
Sources are mostly out of (0)

Similar News Topics

FDA icon

FDA

National Institutes of Health icon

National Institutes of Health

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal